Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety. RESULTS: A total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was -42.8% in the nemolizumab group and -21.4% in the placebo group (difference, -21.5 percentage points; 95% confidence interval, -30.2 to -12.7; P<0.001). The mean percent change in the EASI score was -45.9% with nemolizumab and -33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo. CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The EASI score showed a moderate improvement of 46% with nemolizumab versus 33% in the placebo group192.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
In the citing paper
“The overall efficacy in pruritus in combination with TCSs was further confirmed in a phase III study over 16 weeks with a decrease of 43% versus 21% in the placebo group as measured by the visual analogue scale score.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Research works printed but not linked: 1
- Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019;1:CD012167-CD012167.30666626
Cited by
Ständer, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2023911 · Cited by 756
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Guttman-Yassky, E., Renert-Yuval, Y., & Brunner, P. M. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02519-4 · Cited by 321
Novel insights into atopic dermatitis
Schuler, C. F., Billi, A. C., Maverakis, E., Tsoi, L. C., & Gudjonsson, J. E. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.023 · Cited by 281
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
Facheris, P., Jeffery, J., Del Duca, E., & Guttman-Yassky, E. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00992-4 · Cited by 237
Interleukin‐31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M., & Buddenkotte, J. (2021) · Allergy · doi:10.1111/all.14791 · Cited by 228
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Lynde, C., De Bruin-Weller, M. S., Nahm, W. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301333 · Cited by 193
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190
Fang, Z., Li, L., Zhang, H., Zhao, J., Lu, W., & Chen, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720393 · Cited by 200
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
Dubin, C., Del Duca, E., & Guttman-Yassky, E. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1940962 · Cited by 181
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
Nakashima, C., Yanagihara, S., & Otsuka, A. (2022) · Allergology International · doi:10.1016/j.alit.2021.10.004 · Cited by 192
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 195
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.029 · Cited by 168
Drucker, A. M., Morra, D. E., Prieto-Merino, D., Ellis, A. G., Yiu, Z. Z. N., Rochwerg, B., Di Giorgio, S., Arents, B. W. M., Burton, T., Spuls, P. I., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0455 · Cited by 171
Silverberg, J. I., Wollenberg, A., Reich, A., Thaçi, D., Legat, F. J., Papp, K. A., Gold, L. S., Bouaziz, J., Pink, A., Carrascosa, J. M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01203-0 · Cited by 174
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Müller, S., Maintz, L., & Bieber, T. R. M. (2024) · Allergy · doi:10.1111/all.16009 · Cited by 175
Furue, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113741 · Cited by 168
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Ratchataswan, T., Banzon, T. M., Thyssen, J. P., Weidinger, S., Guttman‐Yassky, E., & Phipatanakul, W. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.034 · Cited by 160
Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies
Bawany, F., Northcott, C. A., Beck, L. A., & Pigeon, W. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.12.007 · Cited by 233
Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M., & for the Nemolizumab JP01 andJP02 Study Group (2021) · British Journal of Dermatology · doi:10.1111/bjd.20873 · Cited by 146
Self-citationButler, D. C., Berger, T. G., Elmariah, S. B., Kim, B., Chisolm, S., Kwatra, S. G., Mollanazar, N. K., & Yosipovitch, G. (2024) · JAMA · doi:10.1001/jama.2024.4899 · Cited by 147
Interleukin-31 as a Clinical Target for Pruritus Treatment
Kabashima, K., & Irie, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.638325 · Cited by 133
Self-citationFXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2024) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 117
Drucker, A. M., Lam, M., Prieto‐Merino, D., Malek, R., Ellis, A. G., Yiu, Z. Z. N., Rochwerg, B. N., Giorgio, S. D., Arents, B. W. M., Mohan, T., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.2192 · Cited by 115
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Kader, H. A., Azeem, M., Jwayed, S. A., Al-Shehhi, A., Tabassum, A., Ayoub, M. A., Hetta, H. F., Waheed, Y., Iratni, R., Aldhaheri, A., et al. (2021) · Cells · doi:10.3390/cells10061392 · Cited by 105
Genetic and Immunological Pathogenesis of Atopic Dermatitis
Schuler, C. F., IV, Tsoi, L. C., Billi, A. C., Harms, P. W., Weidinger, S., & Gudjonsson, J. E. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.10.019 · Cited by 106
Hashimoto, T., Yokozeki, H., Karasuyama, H., & Satoh, T. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.11.009 · Cited by 96
Kamata, M., & Tada, Y. (2023) · JID Innovations · doi:10.1016/j.xjidi.2023.100195 · Cited by 101
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
Haddad, E., Cyr, S. L., Arima, K., McDonald, R. A., Levit, N. A., & Nestle, F. O. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00737-7 · Cited by 102
Challenges and Future Trends in Atopic Dermatitis
Gatmaitan, J. G., & Lee, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411380 · Cited by 110
Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options
Bieber, T. R. M., Paller, A. S., Kabashima, K., Feely, M. A., Rueda, M. J., Terres, J. A. R., & Wollenberg, A. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18225 · Cited by 103
Self-citationTherapeutic monoclonal antibodies in allergy: Targeting IgE , cytokine, and alarmin pathways
Eggel, A., Pennington, L. F., & Jardetzky, T. S. (2024) · Immunological Reviews · doi:10.1111/imr.13380 · Cited by 94
From Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 93
Fassett, M. S., Bráz, J. M., Castellanos, C. A., Salvatierra, J. J., Sadeghi, M., Yu, X., Schroeder, A., Caston, J., Muñoz-Sandoval, P., Roy, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abi6887 · Cited by 86
Daily Lifestyle and Inflammatory Skin Diseases
Sawada, Y., Saito‐Sasaki, N., Mashima, E., & Nakamura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105204 · Cited by 90
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
T‐cell subsets in the skin and their role in inflammatory skin disorders
Krohn, I. K., Aerts, J. L., Breckpot, K., Goyvaerts, C., Knol, E. F., van Wijk, F., & Gutermuth, J. (2021) · Allergy · doi:10.1111/all.15104 · Cited by 93
Stříž, I., Golebski, K., Strizova, Z. O., Loukides, S., Bakakos, P., Hanania, N. A., Jeseňák, M., & Diamant, Z. (2023) · Clinical Science · doi:10.1042/cs20190281 · Cited by 83
Yamamura, Y., Nakashima, C., & Otsuka, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1342176 · Cited by 99
Butala, S., Castelo‐Soccio, L. A., Seshadri, R., Simpson, E. L., O’Shea, J. J., Bieber, T. R. M., & Paller, A. S. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.03.011 · Cited by 71
Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01741-z · Cited by 68
Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch
Takahashi, S., Ochiai, S., Jin, J., Takahashi, N., Toshima, S., Ishigame, H., Kabashima, K., Kubo, M., Nakayama, M., Shiroguchi, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113433 · Cited by 73
Self-citationSeladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Kremer, A. E., Mayo, M. J., Hirschfield, G. M., Levy, C., Bowlus, C. L., Jones, D. E., Johnson, J. D., McWherter, C. A., & Choi, Y.-J. (2024) · Hepatology · doi:10.1097/hep.0000000000000728 · Cited by 61
Ständer, S., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C. F., Simon, D., Naldi, L., Metz, M., Tsianakas, A., Pink, A., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.4796 · Cited by 66
Kim, R. W., Lam, M., Abuabara, K., Simpson, E. L., & Drucker, A. M. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00837-w · Cited by 72
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Interleukin-31 and Pruritic Skin
Furue, M., & Furue, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091906 · Cited by 69
Xu, J., Wang, Y., Khoshdeli, M., Peach, M., Chuang, J.-C., Lin, J. H., Tsai, W., Mahadevan, S., Minto, W. C., Diehl, L. J., et al. (2022) · Hepatology · doi:10.1002/hep.32599 · Cited by 66
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
Alvarenga, J. M., Bieber, T. R. M., & Torres, T. R. (2024) · Drugs · doi:10.1007/s40265-024-02095-4 · Cited by 64
Igarashi, A., Katsunuma, T., Matsumura, T., Komazaki, H., for the Nemolizumab-JP04 Study Group, Takahashi, H., Miura, K., Horino, S., Yoshihara, S., Maeda, S., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad268 · Cited by 60
Self-citationPareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., & Chuturgoon, A. A. (2024) · Cells · doi:10.3390/cells13050425 · Cited by 69
Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans
Nakajima, S., Tie, D., Nomura, T., & Kabashima, K. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155664 · Cited by 62
Self-citationEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17544 · Cited by 59
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
Orfali, R. L., & Aoki, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020577 · Cited by 58
Laska, J., Tota, M., Łacwik, J., Sędek, Ł., & Gomułka, K. (2024) · Cells · doi:10.3390/cells13161398 · Cited by 60
Agache, I. O., Akdiş, C. A., Akdiş, M., Brockow, K., Chivato, T., Giacco, S. D., Eiwegger, T., Eyerich, K., Giménez‐Arnau, A. M., Gutermuth, J., et al. (2020) · Allergy · doi:10.1111/all.14690 · Cited by 56
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
Rewerska, B., Sher, L., Alpizar, S., Pauser, S., Pulka, G., Mozaffarian, N., Salhi, Y., Martinet, C., Jabert, W., Gudi, G. S., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100195 · Cited by 63
Maintz, L., Bieber, T. R. M., Simpson, H. D., & Demessant‐Flavigny, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060893 · Cited by 61
The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
David, E., Ungar, B., Renert‐Yuval, Y., Facheris, P., DUCA, E. D., & Guttman‐Yassky, E. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14263 · Cited by 52
Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics
Bai, R., Zheng, Y., & Dai, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00313-3 · Cited by 58
Immunopathology and Immunotherapy of Inflammatory Skin Diseases
Song, A., Lee, S. E., & Kim, J. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e7 · Cited by 53
Biologics for allergic and immunologic diseases
Morita, H., Matsumoto, K., & Saito, H. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.009 · Cited by 52
Morizane, S., Mukai, T., Sunagawa, K., Tachibana, K., Kawakami, Y., & Ouchida, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239598 · Cited by 46
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment
Wong, L., & Yen, Y.-T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012390 · Cited by 48
Yang, X., Kambe, N., Takimoto‐Ito, R., & Kabashima, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107830 · Cited by 45
Self-citationTopical therapy of atopic dermatitis with a focus on pimecrolimus
Luger, T. A., Paller, A. S., Irvine, A. D., Sidbury, R., Eichenfield, L. F., Werfel, T., & Bieber, T. R. M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17272 · Cited by 43
Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives
Kahremany, S., Hofmann, L., Harari, M., Gruzman, A., & Cohen, G. (2021) · Pharmacological Reports · doi:10.1007/s43440-020-00206-y · Cited by 41
Atopic Dermatitis Itch: Scratching for an Explanation
Soares, G. B., Hashimoto, T., & Yosipovitch, G. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.10.048 · Cited by 44
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis
Yang, N., Chen, Z., Zhang, X., & Shi, Y. (2021) · BioDrugs · doi:10.1007/s40259-021-00490-x · Cited by 39
The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases
Turchin, I., & Bourcier, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02241-y · Cited by 39
The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis
Wong, L., Yen, Y.-T., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137227 · Cited by 36
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
de Bruin-Weller, M. S., Boesjes, C. M., Achten, R., Beck, L. A., Irvine, A. D., Vestergaard, C., de Graaf, M., van Wijk, F., Bakker, D. S., & Weidinger, S. (2025) · Allergy · doi:10.1111/all.70061 · Cited by 40
European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
Weißhaar, E., Müller, S., Szepietowski, J. C., Dalgard, F. J., Garcovich, S., Kupfer, J. P., Giménez‐Arnau, A. M., Lambert, J. R., Mettang, T., Misery, L., et al. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44220 · Cited by 38
Management of Severe Atopic Dermatitis in Pediatric Patients
Mancuso, J., Lee, S. S., Paller, A. S., Ohya, Y., & Eichenfield, L. F. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.017 · Cited by 34
Connections between Immune-Derived Mediators and Sensory Nerves for Itch Sensation
Toyama, S., Tominaga, M., & Takamori, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212365 · Cited by 36
The translational revolution of itch
Kim, B. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.031 · Cited by 35
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 39
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2025) · Allergology International · doi:10.1016/j.alit.2025.01.003 · Cited by 37
Rodríguez, J., Alcantara‐Luna, S., Dominguez‐Cruz, J. J., Galán‐Gutiérrez, M., Ruíz‐Villaverde, R., Vilar-Palomo, S., & Hita, J. C. A. (2021) · Life · doi:10.3390/life11090927 · Cited by 39
Impact of a Decade of Research Into Atopic Dermatitis
Arkwright, P. D., & Koplin, J. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.021 · Cited by 34
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Trier, A. M., & Kim, B. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac016 · Cited by 33
Type 2 immunity‐driven diseases: Towards a multidisciplinary approach
Hassoun, D., Malard, O., Barbarot, S., Magnan, A., & Colas, L. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14029 · Cited by 33
Fukuda, K., Kishimoto, T., Sumi, T., Yamashiro, K., & Ebihara, N. (2022) · Allergology International · doi:10.1016/j.alit.2022.09.005 · Cited by 33
Kołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
“In the phase III trial, the pa‐ tients who could not achieve proper control of pruritus by solely using topical treatment were recruited and enrolled [56].”
BackgroundMethodIL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
Roh, Y. S., Choi, J., Sutaria, N. H., Belzberg, M., Kwatra, M. M., & Kwatra, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01521-1 · Cited by 31
Current Perspectives on the Systemic Management of Atopic Dermatitis
Davari, D. R., Nieman, E. L., McShane, D. B., & Morrell, D. S. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s287638 · Cited by 34
Neuron‒Mast Cell Cross-Talk in the Skin
Zhang, S., Sumpter, T. L., & Kaplan, D. H. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.006 · Cited by 31
Serra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.12.014 · Cited by 31
Emerging concepts in neuropathic and neurogenic itch
Auyeung, K. L., & Kim, B. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.08.008 · Cited by 31
Świerczyńska-Mróz, K., Krajewski, P. K., Nowicka‐Suszko, D., Białynicki‐Birula, R., Krajewska, M., & Szepietowski, J. C. (2022) · Toxins · doi:10.3390/toxins14030197 · Cited by 30
The pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
Emerging treatments for itch in atopic dermatitis: A review
Labib, A., Ju, T., & Yosipovitch, G. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.04.057 · Cited by 31
Kaczmarska, A., Kwiatkowska, D., Skrzypek, K. K., Kowalewski, Z. T., Jaworecka, K., & Reich, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914734 · Cited by 29
The pruritogenic role of the type 2 immune response in diseases associated with chronic itch
Ingrasci, G., Lipman, Z. M., Hawash, A. A., Girolomoni, G., & Yosipovitch, G. (2021) · Experimental Dermatology · doi:10.1111/exd.14401 · Cited by 30
Liang, J., Hu, F., Dan, M., Sang, Y., Abulikemu, K., Wang, Q., Hong, Y., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825312 · Cited by 30
Meixiong, J., Dong, X., & Weng, H.-J. (2020) · Cells · doi:10.3390/cells9102263 · Cited by 31
Metadata
- Authors
- Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M.
- Affiliations
- Kyoto University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-09
- Volume
- 383
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040869725
- Cited by
- 361
- References
- 39
- Citations by year
- 2026: 37 · 2025: 68 · 2024: 57 · 2023: 67 · 2022: 51 · 2021: 73 · 2020: 7
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Maruho co., Ltd.
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, pruritus, nemolizumab, monoclonal antibodies, topical corticosteroids, topical calcineurin inhibitors, Eczema Area and Severity Index, Dermatology Life Quality Index, insomnia, Japanese patients, treatment efficacy and safety, visual analogue scale
- MeSH terms
- Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Dermatitis, Atopic, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Histamine Antagonists, Humans, Injections, Subcutaneous, Male, Middle Aged, Pruritus, Young Adult, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Visual Analog Scale, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.